SUPN

#1830
Supernus Pharmaceuticals, Inc. - Common Stock
43.9 4 USD
0.00%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
43.71
43.96
Intervallo Annuale
42.45
59.68
Variazione giornaliera
+0.46%
Variazione Mensile
-12.90%
Variazione di 6 mesi
-19.03%
Variazione Annuale
-18.63%
Chiusura Precedente
43.7 4
Open
43.8 5
Minimo
43.7 1
Massimo
43.9 6
Volume
57
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K

SUPERNUS PHARMACEUTICALS, INC. current report, 13 July 2021

Full document

Business Context and Reporting Period

This Form 8-K was filed by Supernus Pharmaceuticals, Inc. on July 13, 2021. The report details the entry into a Material Definitive Agreement regarding the supply of active pharmaceutical ingredients (API) for the Company's product Qelbree, which was FDA-approved on April 2, 2021, and commercially launched on May 24, 2021.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual agreement rather than financial performance results.

Material Changes and Agreements

On July 13, 2021, Supernus entered into an API Supply Agreement with Bachem Americas, Inc. Key terms include:

  • Scope: Bachem will manufacture, process, test, store, and package viloxazine hydrochloride (the API in Qelbree) at its cGMP-compliant facility in Switzerland.
  • Equipment: Supernus is responsible for purchasing and installing manufacturing equipment at Bachem's facility. Bachem will handle ordering, installation, qualification, and validation. Title to the equipment remains with Bachem.
  • Exclusivity: Bachem will supply the API exclusively to Supernus during the term.
  • Duration: The agreement runs until July 13, 2026, with automatic two-year extensions unless terminated by notice.
  • Pricing: Prices paid by Supernus include labor, chemicals, packaging, testing, and cleaning costs.

Outlook, Risks, and Management Commentary

The agreement secures the supply chain for Qelbree, a treatment for pediatric ADHD. The filing notes that the full text of the agreement will be filed as an exhibit to the Quarterly Report on Form 10-Q for the period ended June 30, 2021. No specific risks, contingencies, or unusual items beyond the standard contractual obligations are detailed in this summary.

Investor Verification Checklist

  • Verify the full terms of the API Supply Agreement in the upcoming Form 10-Q exhibit.
  • Confirm the timeline for equipment installation and validation at the Swiss facility.
  • Monitor Qelbree commercial launch performance following the May 24, 2021 launch date.
  • Review future 10-Q filings for any financial impact related to equipment costs and API pricing.

Notizie